ArticleCureus2026
Region-Specific Alterations in the Trabecular Meshwork in High- and Low-Tension Glaucoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluates histomorphometric and immunohistochemical changes in the ex vivo trabecular meshwork (TM) of high-pressure glaucoma (HPG) and normal tension glaucoma (NTG) compared to controls from donor corneoscleral buttons. METHODOLOGY: TM specimens were collected from patients with primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACD), pseudoexfoliation glaucoma (XFG), juvenile open-angle glaucoma (JOAG), and normal-tension glaucoma (NTG) who underwent ab-interno trabeculectomy (2020-2023). Controls were obtained within three to six hours postmortem. The TM beam width in each zone was compared qualitatively with controls and between groups. At the same time, nucleated cell count and epithelial-mesenchymal transformation (EMT) changes were analyzed using ImageJ. Immunohistochemistry was used to identify expression of markers such as angiopoietin-like 1 (ANGPTL1), R-spondin 2 (RSPO2), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), alpha-smooth muscle actin (α-SMA), and Collagen IV (COLL4) in TM regions across different glaucoma cases and controls.
resultsJOAG, POAG, and PACD exhibited reduced TM beam width, lower nucleated cell counts, and EMT changes in the CSM > JCT regions compared with controls, with JOAG showing the greatest cell loss. XFG and NTG exhibited preserved JCT nucleated cell counts with maximum ANGPTL1 expression in the JCT region in these eyes. Pronounced EMT changes and α-SMA/COLL4 or LYVE1 expression were seen in all glaucoma cases/controls, while RSPO2 expression was seen only in glaucoma. Conclusions: Distinct histopathological and immunohistochemical changes in TM regions across HTG and NTG suggest different molecular mechanisms of TM damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.